

**FOTIVDA  
(tivozanib)**

**Pre - PA Allowance**

None

---

**Prior-Approval Requirements**

**Age** 18 years of age or older

**Diagnosis**

Patient must have **ONE** of the following:

1. Relapsed or refractory advanced renal cell carcinoma (RCC)
  - a. Patient has had **TWO** or more prior systemic therapies
  - b. Patient has clear cell histology

**AND ALL** of the following:

- a. Prescriber agrees to monitor and control blood pressure using anti-hypertensive therapy when indicated
- b. Prescriber agrees to monitor for cardiac failure and thromboembolic events
- c. Prescriber agrees to discontinue if the patient develops reversible posterior leukoencephalopathy syndrome (RPLS)
- d. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Fotivda and for 1 month after the last dose
- e. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Fotivda and for 1 month after the last dose

**Prior - Approval Limits**

**Quantity** 63 capsules per 84 days

**Duration** 12 months

---

**Prior – Approval *Renewal* Requirements**

**Age** 18 years of age or older

**Diagnosis**



**BlueCross  
BlueShield**

Federal Employee Program.

**FOTIVDA  
(tivozanib)**

Patient must have **ONE** of the following:

1. Relapsed or refractory advanced renal cell carcinoma (RCC)

**AND ALL** of the following:

- a. **NO** disease progression or unacceptable toxicity
- b. Prescriber agrees to monitor and control blood pressure using anti-hypertensive therapy when indicated
- c. Prescriber agrees to monitor for cardiac failure and thromboembolic events
- d. Prescriber agrees to discontinue if the patient develops reversible posterior leukoencephalopathy syndrome (RPLS)
- e. Females of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Fotivda and for 1 month after the last dose
- f. Males with female partners of reproductive potential **only**: patient will be advised to use effective contraception during treatment with Fotivda and for 1 month after the last dose

**Prior - Approval *Renewal* Limits**

Same as above